SCIENCE

We follow the evidence.
Here's where to start.

Curated podcasts, conversations, and research — organized so you can go as deep as you want.

IF YOU'RE NEW TO PEPTIDES

Dr. Craig Koniver | Huberman Lab

Peptide & Hormone Therapies for Health, Performance & Longevity

A board-certified physician walks through GLP-1 analogs, BPC-157, growth hormone peptides, NAD supplementation, and sourcing considerations. One of the most comprehensive and accessible conversations on peptide therapy available.

GO DEEPER ON THE SCIENCE

Dr. Abud Bakri | Huberman Lab

Peptides Masterclass

Almost nobody actually understands peptides. This episode fixes that — covering BPC-157, TB-500, GLP-1s, receptor mechanisms, and the regulatory landscape around compounding pharmacies.

FOR THE LONGEVITY ANGLE

The Peter Attia Drive

Exercise, Nutrition, Hormones for Vitality & Longevity

Peter Attia’s framework for aging well, including his take on NAD+, peptides, and the difference between what has clinical evidence and what doesn’t. Rigorous, honest, and essential listening.

FOR THE BIOHACKER PERSPECTIVE

The Tim Ferriss Show

BPC-157 and Peptide Stacks

One of the most intellectually honest framings in the public record on using peptides as part of a structured protocol — not as a replacement for proven interventions, but as a carefully evaluated addition.

KEY
RESEARCH

BPC-157

Gastric pentadecapeptide BPC-157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocyte growth

— Journal of Orthopaedic Research

BPC-157 and its role in accelerating musculoskeletal soft tissue healing

— Cell and Tissue Research

NAD+

Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis

— Nutrition & Metabolism, 2022

RETATRUTIDE

TRIUMPH-1 trial (Eli Lilly, May 2026) — triple receptor agonist efficacy and body composition outcomes

SCIENCE

We are honest about where the science stands.

Some compounds in our catalog have robust clinical trial data. Others have strong animal model evidence and growing human anecdotal support, but are still awaiting large-scale human trials. We distinguish between the two — and we’ll always tell you which is which.

If the science isn’t there, the product isn’t here.